News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Bitcoin, Gold, or Silver?—ChatGPT, Claude, and Grok Predicts the Front Runner
CoinEdition·2026/03/19 12:24
Bitcoin, Gold, or Silver?—ChatGPT, Claude, and Grok Predicts the Front Runner
CoinEdition·2026/03/19 12:24
XRP Surges Past $1.50 Neckline, Eyes $1.80 Next
CoinEdition·2026/03/19 12:24
US: Slowing spending under Oil shock – TD Securities
101 finance·2026/03/19 12:24
CHF: Dovish SNB stance with benign inflation – ING
101 finance·2026/03/19 12:24
Gold price sees central bank headwinds as BoE keeps rates unchanged
101 finance·2026/03/19 12:22
February 2026 Monthly Release
Finviz·2026/03/19 12:22
CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER
Finviz·2026/03/19 12:16
Zcash Is Crypto’s Most Mispriced Asset, Cypherpunk CIO Says
Newsbtc·2026/03/19 12:06
Bitcoin whales move millions as Iran war sends oil surging
Cointelegraph·2026/03/19 12:06
Flash
20:09
Five Below shares dropped 8% in after-hours US tradingThe company's net sales in the first quarter were $1.29 billion.
20:06
U.S. stocks close lower: the three major indexes ended in the red, NVIDIA fell more than 3%According to Golden Ten Data on June 4, U.S. stocks closed lower on Wednesday, with the Dow Jones initially down 1.2%, the S&P 500 down 0.7%, and the Nasdaq down 0.89%. Microsoft (MSFT.O) and NVIDIA (NVDA.O) both fell more than 3%, Oracle (ORCL.N) dropped over 5%, while Intel (INTC.O) rose 4%. The Nasdaq Golden Dragon China Index closed down 2.46%, with Alibaba (BABA.N) slipping more than 2%.
20:06
Verastem Oncology announced that its oral, potential best-in-class investigational KRAS G12D (on/off) inhibitor VS-7375 has received Fast Track designation from the U.S. Food and Drug Administration (FDA).This medication is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the KRAS G12D mutation. Fast Track designation is designed to accelerate the development and review process for drugs aimed at serious conditions that address unmet medical needs. This designation means that VS-7375 has the potential to address the critical clinical need in KRAS G12D-mutant NSCLC. For Verastem, this represents an important regulatory milestone in advancing its product pipeline.